Medical device and MedTech insights, news, tips and more

Heart Test Labs Appoints Industry Veteran Brian Allen as it Prepares for Commercial Device Launch

November 11, 2016

Heart Test

Heart TestWESTLAKE, Texas–(BUSINESS WIRE)–Heart Test Laboratories Inc., announced today the appointment of Brian L. Allen as Senior Vice President of Business Development. In this role, Mr. Allen will lead the company’s commercial launch of its MyoVista electrocardiographic device. He will be responsible for building the sales team and distribution partners on a global basis. Mr. Allen joins the senior executive team and will report directly to Mark Hilz, Heart Test Laboratories’ Chief Executive Officer.

Heart TestMr. Allen has 20 plus years of medical device experience that includes an accomplished track record of multiple first-to-market medical device innovations by developing strategies and building successful sales teams that achieved successful market adoption. Mr. Allen joins Heart Test Laboratories as it is preparing for commercialization after having recently submitted a 510k application to the FDA and CE Mark technical file for approval. “We are excited to have an executive of Brian’s caliber and experience leading our commercialization efforts. Brian brings to Heart Test Laboratories a strong track record of developing and executing multiple successful commercialization efforts in the medical device market,” said Hilz.

Recently, Mr. Allen served as Vice President of Sales and Commercial Marketing for OrthoSensor Inc., where he led the planning and successful launch of their global sales and market expansion through distribution partners. Prior to that, he led the company’s domestic sales strategy, and was responsible for launch which included sales, marketing and market education of VERASENSE, the orthopedic industry’s first Sensor-assisted technology used in Total Knee Replacement Surgery.

Before joining OrthoSensor, Mr. Allen served as Director of Sales and Marketing for MAKO Surgical Corp. responsible for planning and executing the commercial market launch and sustainable growth of the orthopedic industry’s first Robotic-assisted Surgery system and novel implants. MAKO Surgical Corp. was acquired by Stryker Inc. for $1.65B (2013).

Early in his career, Mr. Allen held various progressive sales and leadership roles at Medtronic Neurological and Coronary Vascular business units, Zimmer Inc. and Burrows Inc., which subsequently was acquired by Owens and Minor, Inc.

“Meaningful innovation that has the potential to improve clinical care, reduce care-pathway costs and significantly enhance and extend the quality of life of patients, inspires and excites me. MyoVista® is poised to transform the early detection of heart disease and establish a new benchmark for heart disease screening,” stated Mr. Allen.

The search was conducted for Heart Test Labs by Paula Rutledge of Legacy MedSearch.

About Heart Test Laboratories, Inc. (“HTL”)

HTL develops medical devices using patented proprietary technology that focus on the early detection of heart disease. MyoVista’s innovative technology facilitates the early identification of ischemic and other heart myocardial dysfunctions, which can enable improved screening for coronary arterial disease and other cardiac abnormalities. MyoVista® uses standard 12-lead resting ECG protocols to provide a traditional ECG incorporating interpretive analysis, as well as further proprietary informatics to assist a physician in identifying the presence of heart disease. MyoVista® is ideally suited for use in both primary care and hospital environments, and has a 15.6-inch high-resolution touchscreen and incorporates many user features and functionality commonly associated with a tablet device, which makes it intuitive and easy to use, thereby reducing training time.

Heart Disease kills 7 million people worldwide each year, more than all cancers combined, and is the largest spend area in healthcare. MyoVista® helps to bridge the “diagnostic gap” in heart disease today, which is the identification of patients prior to an adverse cardiac event, such as a heart attack.

Heart Test Laboratories is a privately held U.S. corporation which to date has been funded by private investors. For more information, visit

Source: Heart Test Labs Appoints Industry Veteran Brian Allen as it Prepares for Commercial Launch of its MyoVista Medical Device | Business Wire

More insights

March 7, 2024
FDA Clears Dexcom’s First Over-the-Counter Continuous Glucose Monitor
Learn More
March 1, 2024
FDA greenlights Boston Scientific’s Novel Drug-Coated Balloon for Coronary In-Stent Restenosis
Learn More
February 21, 2024
Sparrow BioAcoustics Launches Software That Turns a Smartphone into a Stethoscope 
Learn More

Begin your legacy now. We are your medtech and medical device talent advisory firm.